Trius Therapeutics
FacebookTwitterLinkedin
Best in Class Anti-Infectives
  • About
    • About Trius
    • Management
    • Board of Directors
    • Clinical Advisory Board
    • Scientific Advisory Board
    • Jeff Stein's Blog
  • Pipeline
    • PIPELINE
    • TEDIZOLID OVERVIEW
    • GyrB/ParE PROGRAM
    • MurB PROGRAM
  • Research/Development
    • Research/Development
    • Clinical Studies
  • Investor Relations
  • Publications & Posters
    • ECCMID 2013
  • Careers
  • Contact Us
  • 2010 ONLINE ANNUAL REPORT
  • 2011 ONLINE ANNUAL REPORT
  • 2012 ONLINE ANNUAL REPORT
    • LETTER TO THE SHAREHOLDERS
    • DEVELOPMENT PROGRAMS/
      MARKET OPPORTUNITIES
    • COMPLETE 2012 ANNUAL
      REPORT [PDF]
    • FORM 10K
      1. Business
      2. Risk Factors
      3. Legal Proceedings
      4. Selected Financial Data
      5. Management's Discussion and Analysis of Financial Condition and Results Operations
      6. Quantitative and Qualitative Disclosures about Market Risk
      7. Financial Statements and Supplementary Data
Search | Terms of Use | Privacy Policy
© 2013 Trius Therapeutics. No portion of this website may be duplicated, redistributed or manipulated in any form. All rights reserved.